Randomized trial · people
MK-677 plus alendronate: 4.2% femoral neck BMD gain vs 2.5% alone
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In older women with osteoporosis, MK-677 raised IGF-1 and bone turnover markers, but adding it to alendronate improved bone density only at the femoral neck, which the authors weighed against growth hormone side effects.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 292
- Published
- 2001
- Journal
- J Clin Endocrinol Metab
What they tested
The team tested whether adding MK-677 to alendronate, a bone loss drug, would keep bone building higher and raise bone density more than alendronate alone in women with postmenopausal osteoporosis.
How the study was done
A multicenter, randomized, double-blind, placebo-controlled trial in 292 women aged 64 to 85 with low femoral neck bone density. For 12 months they took daily MK-677 25 mg plus alendronate 10 mg, alendronate alone, MK-677 alone, or placebo (dummy pills). The MK-677-alone and placebo groups then switched to the combination for months 12 to 18, and everyone took 500 mg/day calcium.

What they found
At 12 months, IGF-1 (insulin-like growth factor I) rose 39% and 45% from baseline in the two groups taking MK-677, compared with placebo. MK-677 alone raised osteocalcin, a blood marker of bone formation, by 22% and urinary NTx, a marker of bone breakdown, by 41% versus placebo. Compared with alendronate alone, the combination softened the drop in osteocalcin (-40% vs. -54%) and in NTx (-52% vs. -61%). Bone mineral density at the femoral neck rose 4.2% with the combination versus 2.5% with alendronate, but the combination did no better at the lumbar spine, total hip or total body.
What it doesn’t show
The extra bone density gain showed up at only one of four sites measured, and people taking MK-677 had side effects linked to higher growth hormone, though few quit because of them. The trial included only older women with postmenopausal osteoporosis, and bone marker results were for 12 months.
The paper
Murphy et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2001.
The compound
More studies on MK-677
- MK-677 raised IGF-1 but not most function after hip fractureRandomized trial · people · 2011
- MK-677: fat-free mass rose 1.1 kg vs -0.5 kg on placebo at 1 yearRandomized trial · people · 2008
- MK-677 raised bone turnover markers in adults 65 and olderRandomized trial · people · 1999
- MK-677 reversed diet-driven nitrogen loss in 8 healthy adultsRandomized trial · people · 1998
- MK-677: IGF-I rose 52% at 10 mg and 79% at 50 mg in GH-deficient menRandomized trial · people · 1997
- MK-677: moderate GH isoform shifts over 8 weeks in obese menClinical trial · people · 2003
- Every study on MK-677
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.